Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spatial Fractionated SBRT + toripalimab + chemotherapy vs toripalimab + chemotherapy in resectable stage II–III NSCLC
ChiCTR2600129470Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised trial of toripalimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 2-year event-free survival rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600129470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129470.